Novartis has entered into an agreement to acquire Synnovation Therapeutics' pan-mutant-selective PI3Kα inhibitor, SNV4818, in a transaction valued at up to USD 3 billion. The deal includes a USD 2 billion upfront payment and up to USD 1 billion in potential milestone payments. Novartis will acquire Pikavation Therapeutics, a wholly owned subsidiary of Synnovation that holds SNV4818 and similar assets, with the transaction expected to close in H1 2026.

SNV4818 is an oral therapy currently in Phase I/II trials for breast cancer and other advanced solid tumours. It is designed to selectively inhibit mutant forms of the PI3Kα enzyme, which are implicated in approximately 40% of HR+/HER2- breast cancers, while sparing the wild-type enzyme. This selectivity aims to improve tolerability compared to existing PI3Kα inhibitors, potentially enabling more durable treatment and easier combination with standard therapies like CDK4/6 and endocrine treatments.

According to PharmCube's NextBiopharm® database, this is the largest deal reported for a PI3Kα H1047X Inhibitor. Click here to request a free trial for NextBiopharm®.